USO 24186
A Phase 3, Randomized, Open-label, Multicenter Study of Sacituzumab Tirumotecan (sac-TMT, MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly Diagnosed Advanced HRD-Negative Ovarian Cancer Following First-line Platinum-based Chemotherapy (TroFuse-021/ENGOT- ov85/GOG-3102)
Disease Types: GYN Cancer Research
Eligibility Requirements:
• Confirmed FIGO Stage III or IV epithelial OC/FT/PPC
• Allows high-grade serous, endometrioid, carcinosarcoma/mixed
Müllerian with high-grade serous component, clear cell, low-grade
serous histologies
• Has undergone debulking surgery (primary [PDS] or interval [IDS])
• Must have completed 4-6 cycles of 1L plt-based chemo
• For IDS: ≥2 but preferably 3 cycles of 1L plt-based chemo after
surgery
• ≤12 weeks between last dose of 1L plt-based chemo and randomization
• Has CR, PR, SD, or NED by the investigator to 1L plt-based chemo at
screening (based on RECIST 1.1 and CA-125 levels and evaluated
between 3-6 weeks after last dose of plt)
• Not eligible to receive PARPi as 1L maintenance tx
• HRD-negative and known TROP2 status by prospective central testing
• Prior tx with TROP2-targeted ADC or topoisomerase I-containing ADCs
are excluded.
For more information on this trial CLICK HERE .
Available at: